Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
Acta Neuropathologica Communications|November 21, 2013
Dysfunction of the mTOR pathway is a risk factor for Alzheimer's diseaseSharon C Yates, Amen Zafar, Paul Hubbard, et al.International Journal of Molecular Epidemiology and Genetics|June 25, 2014
Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluidJoanna L Richens, Kelly-Ann Vere, Roger A Light, et al.BMC Neurology|June 8, 2012
Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysisRebecca Beynon, Jonathan A C Sterne, Gordon Wilcock, et al.Journal of Alzheimer'S Disease : JAD|June 18, 2016
A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative CohortOlivia Anna Skrobot, Amy Jayne McKnight, Peter Anthony Passmore, et al.Journal of Alzheimer'S Disease : JAD|November 3, 2011
Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluidBaharak Vafadar-Isfahani, Graham Ball, Clare Coveney, et al.Journal of Alzheimer'S Disease : JAD|November 14, 2014
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohortJeffrey L Seeburger, Daniel J Holder, Marc Combrinck, et al.Progress in Neurobiology|December 7, 2010
Biomarkers for Alzheimer's disease therapeutic trialsHarald Hampel, Gordon Wilcock, Sandrine Andrieu, et al.JAMA Neurology|November 19, 2019
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical TrialRobert Howard, Olga Zubko, Rosie Bradley, et al.The New England Journal of Medicine|October 5, 2007
Donepezil for the treatment of agitation in Alzheimer's diseaseRobert J Howard, Edmund Juszczak, Clive G Ballard, et al.Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.Pageof 6